Literature DB >> 12767117

Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.

Joong-Youn Shim1, William J Welsh, Allyn C Howlett.   

Abstract

Association of cannabimimetic compounds such as cannabinoids, aminoalkylindoles (AAIs), and arachidonylethanolamide (anandamide) with the brain cannabinoid (CB(1)) receptor activates G-proteins and relays signals to regulate neuronal functions. A CB(1) receptor homology model was constructed using the published x-ray crystal structure of bovine rhodopsin (Palczewski et al., Science, 2000, Vol. 289, pp. 739-745) in the conformation most likely to represent the "high-affinity" state for agonist binding to G-protein coupled receptors (GPCRs). A molecular docking approach that combined Monte Carlo and molecular dynamics simulations was used to identify the putative binding conformations of nonclassical cannabinoid agonists, including AC-bicyclic CP47497 and CP55940, and ACD-tricyclic CP55244. Placement of these ligands was based upon the assumption of a critical hydrogen bond between the A-ring OH and the side chain N of Lys192 in transmembrane helix 3. We evaluated two alternative binding conformations, C3-in and C3-out, denoting the directionality of the ligand C3 side chain within the receptor with respect to the inside or the outside of the cell. Assuming both the C3-in or C3-out conformation, the calculated ligand-receptor binding energy (DeltaE(bind)) was correlated with the experimentally observed binding affinity (K(i)) for a series of nonclassical cannabinoid agonists. The C3-in conformation was marginally better than the alternative C3-out conformation in predicting the rank order of the tested nonclassical cannabinoid analogs. Adopting the C3-in conformation due to the greater number of receptor interactions with known pharmacophoric elements of the ligand, key residues were identified comprising the presumed hydrophobic pocket that interacts with the C3 side chain of cannabinoid agonists. Key hydrogen bonds would form between both K3.28(192) and E(258) and the A-ring OH, and between Q(261) and the C-ring C-12 hydroxypropyl. In summary, the present study represents one of the first attempts to construct a homology model of the CB(1) cannabinoid receptor based upon the published bovine rhodopsin x-ray crystal structure and to elucidate the putative ligand binding site for nonclassical cannabinoid agonists. We postulated sites of the CB(1) receptor critical for the ligand interaction, including the hydrophobic pocket interacting with the key pharmacophoric moiety, the C3 side chain. More work is needed to delineate between two alternative (and possibly other) binding conformations of the nonclassical cannabinoid ligands within the CB(1) receptor. The present study provides a consistent framework for further investigation of the CB(1) receptor-ligand interaction and for the study of CB(1) receptor activation. Copyright 2003 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767117     DOI: 10.1002/bip.10424

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  20 in total

1.  In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.

Authors:  Guanglin Kuang; Guoping Hu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-09       Impact factor: 1.810

2.  FFA1-selective agonistic activity based on docking simulation using FFA1 and GPR120 homology models.

Authors:  Masato Takeuchi; Akira Hirasawa; Takafumi Hara; Ikuo Kimura; Tatsuya Hirano; Takayoshi Suzuki; Naoki Miyata; Takeo Awaji; Masaji Ishiguro; Gozoh Tsujimoto
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

3.  "K2/Spice": have you updated your differentials? A case report.

Authors:  Roopa Sethi; Neha Thapa; Ashwini Saxena; Ritu Chahil
Journal:  Prim Care Companion CNS Disord       Date:  2013

4.  A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis.

Authors:  Serdar Durdagi; Manthos G Papadopoulos; Panagiotis G Zoumpoulakis; Catherine Koukoulitsa; Thomas Mavromoustakos
Journal:  Mol Divers       Date:  2009-06-18       Impact factor: 2.943

Review 5.  Synthetic Pot: Not Your Grandfather's Marijuana.

Authors:  Benjamin M Ford; Sherrica Tai; William E Fantegrossi; Paul L Prather
Journal:  Trends Pharmacol Sci       Date:  2017-02-02       Impact factor: 14.819

Review 6.  Marijuana-based drugs: innovative therapeutics or designer drugs of abuse?

Authors:  Kathryn A Seely; Paul L Prather; Laura P James; Jeffery H Moran
Journal:  Mol Interv       Date:  2011-02

7.  Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Authors:  Benjamin M Ford; Lirit N Franks; Sherrica Tai; William E Fantegrossi; Edward L Stahl; Michael D Berquist; Christian V Cabanlong; Catheryn D Wilson; Narsimha R Penthala; Peter A Crooks; Paul L Prather
Journal:  Pharmacol Res       Date:  2017-08-23       Impact factor: 7.658

8.  Human cannabinoid 1 GPCR C-terminal domain interacts with bilayer phospholipids to modulate the structure of its membrane environment.

Authors:  Elvis K Tiburu; Sergiy Tyukhtenko; Han Zhou; David R Janero; Jochem Struppe; Alexandros Makriyannis
Journal:  AAPS J       Date:  2011-01-14       Impact factor: 4.009

9.  Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling.

Authors:  Teodora Georgieva; Savitha Devanathan; Dagmar Stropova; Chad K Park; Zdzislaw Salamon; Gordon Tollin; Victor J Hruby; William R Roeske; Henry I Yamamura; Eva Varga
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

Review 10.  Marijuana, Spice 'herbal high', and early neural development: implications for rescheduling and legalization.

Authors:  Delphine Psychoyos; K Yaragudri Vinod
Journal:  Drug Test Anal       Date:  2012-08-13       Impact factor: 3.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.